文献速递头痛与眩晕

依瑞奈珠单抗治疗慢性偏头痛:随机双盲研究中患者报告结局

Erenumab in chronic migraine: Patient-reported outcomes in a randomized double-blind study.
PubMed 文献 · Neurology · 2019-04-17

这项双盲安慰剂对照研究纳入667例慢性偏头痛成人,按3:2:2随机接受安慰剂或依瑞奈珠单抗70mg/140mg每月治疗。第3个月时,两个剂量组在健康相关生活质量、头痛影响和失能等患者报告结局上均较安慰剂有临床相关改善。

要点

  • 依瑞奈珠单抗70mg和140mg均改善慢性偏头痛患者的生活质量、头痛影响和失能。
  • 第3个月HIT-6评分变化:两个剂量组均为-5.6,安慰剂组为-3.1。
  • 第3个月MIDAS评分变化:70mg组-19.4天,140mg组-19.8天,安慰剂组-7.5天。

核心结论

  • 依瑞奈珠单抗治疗慢性偏头痛患者在广泛患者报告结局上获得临床相关改善。

研究设计与样本

  • 双盲、安慰剂对照研究,纳入667例慢性偏头痛成人,按3:2:2随机分配至安慰剂或依瑞奈珠单抗70mg或140mg每月治疗。

主要发现

  • 第3个月两个剂量组所有终点均改善,第1个月时许多结局已显示较安慰剂更大的变化。
  • 第3个月HIT-6评分变化:两个剂量组均为-5.6,安慰剂组为-3.1。
  • 第3个月MIDAS评分变化:70mg组-19.4天,140mg组-19.8天,安慰剂组-7.5天。
  • 两个剂量组达到MSQ各领域和HIT-6个体水平最小重要差异的参与者比例均高于安慰剂组。
  • 第3个月时,依瑞奈珠单抗组MIDAS评分为重度(≥21)或极重度(≥41)或PROMIS评分≥60的比例低于安慰剂组。

关键数值与推荐

  • MSQ角色功能受限领域最小重要差异≥3.2,情绪功能领域≥7.5,角色功能预防领域≥4.5;140mg组治疗差异超过上述阈值。
  • HIT-6评分第3个月变化:依瑞奈珠单抗70mg和140mg组均为-5.6,安慰剂组为-3.1。
  • MIDAS评分第3个月变化:70mg组-19.4天,140mg组-19.8天,安慰剂组-7.5天。
  • MIDAS重度阈值≥21,极重度阈值≥41;PROMIS评分阈值≥60。

临床怎么用

  • 依瑞奈珠单抗可用于改善慢性偏头痛患者的健康相关生活质量、头痛影响和失能。
  • 临床评估可结合MSQ、HIT-6、MIDAS和PROMIS等患者报告结局工具。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To determine the effect of erenumab, a human monoclonal antibody targeting the calcitonin gene-related peptide receptor, on health-related quality of life (HRQoL), headache impact, and disability in patients with chronic migraine (CM). METHODS: In this double-blind, placebo-controlled study, 667 adults with CM were randomized (3:2:2) to placebo or erenumab (70 or 140 mg monthly). Exploratory endpoints included migraine-specific HRQoL (Migraine-Specific Quality-of-Life Questionnaire [MSQ]), headache impact (Headache Impact Test-6 [HIT-6]), migraine-related disability (Migraine Disability Assessment [MIDAS] test), and pain interference (Patient-Reported Outcomes Measurement Information System [PROMIS] Pain Interference Scale short form 6b). RESULTS: Improvements were observed for all endpoints in both erenumab groups at month 3, with greater changes relative to placebo observed at month 1 for many outcomes. All 3 MSQ domains were improved from baseline with treatment differences for both doses exceeding minimally important differences established for MSQ-role function-restrictive (≥3.2) and MSQ-emotional functioning (≥7.5) and for MSQ-role function-preventive (≥4.5) for erenumab 140 mg. Changes from baseline in HIT-6 scores at month 3 were -5.6 for both doses vs -3.1 for placebo. MIDAS scores at month 3 improved by -19.4 days for 70 mg and -19.8 days for 140 mg vs -7.5 days for placebo. Individual-level minimally important difference was achieved by larger proportions of erenumab-treated participants than placebo for all MSQ domains and HIT-6. Lower proportions of erenumab-treated participants had MIDAS scores of severe (≥21) or very severe (≥41) or PROMIS scores ≥60 at month 3. CONCLUSIONS: Erenumab-treated patients with CM experienced clinically relevant improvements across a broad range of patient-reported outcomes. CLINICALTRIALSGOV IDENTIFIER: NCT02066415. CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that for patients with CM, erenumab treatment improves HRQoL, headache impact, and disability.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Lipton RB, Tepper SJ, Reuter U, et al. Erenumab in chronic migraine: Patient-reported outcomes in a randomized double-blind study. Neurology. 2019. PMID: 30996060. doi:10.1212/WNL.0000000000007452

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。